Diamyd Medical (Germany) Performance
| DMN Stock | EUR 0.99 0.04 4.21% |
The firm shows a Beta (market volatility) of 0.86, which means possible diversification benefits within a given portfolio. Diamyd Medical returns are very sensitive to returns on the market. As the market goes up or down, Diamyd Medical is expected to follow. At this point, Diamyd Medical AB has a negative expected return of -0.39%. Please make sure to confirm Diamyd Medical's mean deviation, information ratio, potential upside, as well as the relationship between the standard deviation and total risk alpha , to decide if Diamyd Medical AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Diamyd Medical AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 139.4 M | |
| Total Cashflows From Investing Activities | -76.7 M |
Diamyd |
Diamyd Medical Relative Risk vs. Return Landscape
If you would invest 132.00 in Diamyd Medical AB on August 29, 2024 and sell it today you would lose (33.00) from holding Diamyd Medical AB or give up 25.0% of portfolio value over 90 days. Diamyd Medical AB is currently producing negative expected returns and takes up 3.4628% volatility of returns over 90 trading days. Put another way, 30% of traded stocks are less volatile than Diamyd, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Diamyd Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diamyd Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diamyd Medical AB, and traders can use it to determine the average amount a Diamyd Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DMN |
Estimated Market Risk
| 3.46 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Diamyd Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diamyd Medical by adding Diamyd Medical to a well-diversified portfolio.
Diamyd Medical Fundamentals Growth
Diamyd Stock prices reflect investors' perceptions of the future prospects and financial health of Diamyd Medical, and Diamyd Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diamyd Stock performance.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 96.81 M | |||
| Shares Outstanding | 76.93 M | |||
| Price To Book | 5.52 X | |||
| Price To Sales | 2,594 X | |||
| Revenue | 454 K | |||
| EBITDA | (98.88 M) | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 236.52 M | |||
About Diamyd Medical Performance
By analyzing Diamyd Medical's fundamental ratios, stakeholders can gain valuable insights into Diamyd Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Diamyd Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diamyd Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.Things to note about Diamyd Medical AB performance evaluation
Checking the ongoing alerts about Diamyd Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diamyd Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diamyd Medical AB generated a negative expected return over the last 90 days | |
| Diamyd Medical AB has some characteristics of a very speculative penny stock | |
| Diamyd Medical AB has high historical volatility and very poor performance | |
| Diamyd Medical AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 454 K. Net Loss for the year was (103.52 M) with loss before overhead, payroll, taxes, and interest of (3.95 M). | |
| Diamyd Medical generates negative cash flow from operations | |
| About 35.0% of the company shares are held by company insiders |
- Analyzing Diamyd Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diamyd Medical's stock is overvalued or undervalued compared to its peers.
- Examining Diamyd Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diamyd Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diamyd Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diamyd Medical's stock. These opinions can provide insight into Diamyd Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Diamyd Stock analysis
When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |